A study of CardioMEMS and HeartMate 3 for advanced heart failure
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests if a combination of a tiny lung-artery pressure sensor (CardioMEMS) and a mechanical heart pump (HeartMate 3) is safe and effective for people with advanced heart failure. If you qualify, you'll either get the heart pump plus standard medical therapy, or continue with standard therapy alone and have your pressure monitored remotely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your heart's pumping ability is very low, with an ejection fraction (LVEF) at or below 30%.
- You have marked limitations even with daily activities (NYHA Class IIIb or IV).
- You have had at least one hospital stay for heart failure in the last year.
- You either already have a CardioMEMS implant in your lung artery or are willing to get one.
- You are willing to receive a HeartMate 3 (HM3) heart pump if you are assigned to that group.
- You do not have any other severe health problems that would make the procedure too risky.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a wearable home monitoring system (myCordella™) can help people with moderate heart failure (NYHA class II or III) by tracking heart pressure and supporting follow-up care. It may help detect changes earlier so clinicians can adjust treatment sooner.
This study tests whether a small sensor (CardioMEMS) implanted in the lung artery can help doctors better manage LVAD settings and reduce hospital visits. It is for people who already have a HeartMate 3 heart pump and are stable enough to go home.
This study is looking at how well the CardioMEMS heart monitor works for people with heart failure. The device is already implanted and tracks pressure in your lung artery to help your doctor manage your condition and potentially prevent hospital visits.
This study checks how safe a small heart-pressure monitoring device is for people with advanced heart failure and severe kidney problems. It looks at whether doctors can continuously track heart filling/pressure to help manage symptoms and reduce risks.
This trial tests if adding the drug vericiguat to standard care can help people with heart failure and a reduced pumping ability who have a CardioMEMS monitor. It looks for improved pressure readings in your lung artery to guide treatment.
This study tests a heart device (CCM) plus standard medications to see if the combination helps people with a weak heart pump. It's for those whose heart function is low and who still have symptoms despite current treatment.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.